ストックスクリーナーアプリを入手
4.115
2.95%
-0.125
Aldeyra Therapeutics Inc (ALDX) 最新ニュース
What to keep an eye on in 2026 - Eyes On Eyecare
Aldeyra Therapeutics Chief Development Officer Stephen Machatha to Resign - marketscreener.com
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Aldeyra Therapeutics chief development officer to step down by March 2026 - Investing.com Nigeria
Aldeyra Therapeutics Announces Chief Development Officer Resignation - TipRanks
Aldeyra Therapeutics Announces Resignation of Chief Development Officer - TradingView — Track All Markets
Aldeyra Therapeutics: Reproxalap’s March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha
Why is Aldeyra Therapeutics stock surging after FDA delayed its dry eye drug decision? - MSN
Why (ALDX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) Institutional Shareholders Had a Great Week as One-year Returns Increased After a 24% Gain Last Week - 富途牛牛
Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Can SAL Steel Limited Maintain Growth Without Diluting ShareholdersLong-Term Investment Plans & Small Investment Capital Gains - earlytimes.in
Targets Report: Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Earnings Recap Report & Weekly Watchlist of Top Performers - Улправда
Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Trade Analysis Report & Daily Market Momentum Tracking - ulpravda.ru
Can Aldeyra Therapeutics Inc. stock rebound after recent weaknessPrice Action & Community Verified Trade Signals - DonanımHaber
What dividend safety score for Aldeyra Therapeutics Inc. stockMarket Trend Summary & Reliable Trade Execution Plans - DonanımHaber
What Wall Street predicts for Aldeyra Therapeutics Inc. stock priceWeekly Stock Summary & Real-Time Market Sentiment Reports - Улправда
Will Aldeyra Therapeutics Inc. stock benefit from infrastructure spendingSwing Trade & Fast Gaining Stock Strategy Reports - Улправда
ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being InvestigatedContact the Firm if You Lost Money - 28/22 News
Aldeyra Therapeutics Earnings Notes - Trefis
Aldeyra Therapeutics Sees Unusually Large Options Volume (NASDAQ:ALDX) - Defense World
Aldeyra drops as FDA delays review of marketing application for lead drug - MSN
Aldeyra Therapeutics Target of Unusually Large Options Trading (NASDAQ:ALDX) - MarketBeat
Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside - TipRanks
Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision? - Asianet Newsable
Aldeyra Therapeutics (NASDAQ: ALDX) updates on FDA review of reproxalap - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Aldeyra stock surges as FDA delays dry eye drug decision | Tap to know more | Inshorts - Inshorts
ALDX: FDA extends reproxalap NDA review by 90 days after requiring field trial CSR submission - TradingView — Track All Markets
FDA Extends Review Timeline For Aldeyra's Dry Eye Disease Drug - Sahm
Aldeyra Therapeutics (ALDX) Faces FDA Review Delay for Reproxala - GuruFocus
Why Is Aldeyra Therapeutics Stock Falling Tuesday?Aldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Transcript : Aldeyra Therapeutics, Inc.Special Call - marketscreener.com
Aldeyra stock drops on FDA delay for lead drug (ALDX:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Aldeyra Therapeutics Faces FDA PDUFA Date Extension - TipRanks
Aldeyra Says FDA Extends Action Date for Potential Dry Eye Disease Treatment; Shares Down Pre-Bell - marketscreener.com
Aldeyra Therapeutics Announces PDUFA Extension for Reproxalap NDA - TradingView — Track All Markets
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Aldeyra (ALDX) Receives Extended FDA Action Date for Reproxalap NDA - GuruFocus
Aldeyra (Nasdaq: ALDX) PDUFA review of reproxalap dry eye NDA extended to Mar. 2026 - Stock Titan
Aldeyra Therapeutics announces PDUFA extension of the new drug application of Reproxalap for the treatment of dry eye disease - marketscreener.com
683 Capital Management LLC Has $4.14 Million Stake in Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Adversity is less terrifying than hope: Aldeyra Therapeutics Inc (ALDX) - setenews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - 28/22 News
Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance
Aldeyra Therapeutics, Inc. $ALDX Shares Sold by Kennedy Capital Management LLC - MarketBeat
Winners Losers: Will Aldeyra Therapeutics Inc stock maintain momentum in 2025 - BỘ NỘI VỤ
It makes sense and dollars to buy Aldeyra Therapeutics Inc (ALDX) stock - setenews.com
Aldeyra Therapeutics Inc (137.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Aldeyra Therapeutics Inc. stock oversold or undervaluedCEO Change & Smart Allocation Stock Reports - Newser
FDA’s docket holds 16 more PDUFA dates by year-end - BioCentury
Can Aldeyra Therapeutics Inc. stock deliver surprise earnings beatChart Signals & Long-Term Capital Growth Strategies - moha.gov.vn
Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet? - simplywall.st
Why retail investors favor Aldeyra Therapeutics Inc. stock2025 Short Interest & Free Growth Oriented Trading Recommendations - newser.com
Biotech Stocks Facing FDA Decision In December 2025 - RTTNews
2.09%
0.56%
大文字化:
|
ボリューム (24 時間):